Results 191 to 200 of about 77,701 (209)
Some of the next articles are maybe not open access.
Evolving standards of care and new challenges in the management of HER2‐positive breast cancer
Ca-A Cancer Journal for Clinicians, 2020Grace M Choong +2 more
exaly
[Angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockers].
Nihon rinsho. Japanese journal of clinical medicine, 2007Masaki, Mogi, Masatsugu, Horiuchi
openaire +1 more source
Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
Journal of human hypertension, 1997Candesartan is a potent and selective angiotensin II type 1 receptor blocker which binds tightly to and dissociates slowly from the AT1 receptor. It is administered orally as the prodrug candesartan cilexetil, which is rapidly and completely converted to the active compound, candesartan, during gastrointestinal absorption.
openaire +1 more source
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Ca-A Cancer Journal for Clinicians, 2020Vaibhav G Patel +2 more
exaly
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Nature Reviews Endocrinology, 2012Juris J Meier
exaly
Interleukin-1–Receptor Antagonist in Type 2 Diabetes Mellitus
New England Journal of Medicine, 2007Allan Vaag +2 more
exaly
Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy
New England Journal of Medicine, 2004Sten Madsbad
exaly